Sarepta Therapeutics shares jump on news of critic’s departure from FDA

"Arguably the most oppositional team leader of the review board to the approval of Duchenne Muscular Dystrophy (DMD)-treating pipeline drug eteplirsen, has officially left the FDA."

Views: 341

Reply to This

Replies to This Discussion

Good riddance! Hopefully he will stay away from all medicine for good. A disgrace to the profession!

Thank you for sharing this.

It says he left to work for  Paraxel a pharmaceutical company that specializes in clinical trials. I wonder if they will be working on a treatment for DMD.  Hmm.

Three cheers for Janet Woodcock! She gets rid of Farkas and just days later we have accelerated approval!!!!

Reply to Discussion


Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service